Unmet need

Three chronic conditions, and the gaps that remain

Type 2 diabetes, obesity and NASH are chronic: treatment is measured in years and decades, so how a therapy is taken matters as much as what it does. Our programmes target the specific gaps left by current standard of care.

DecadesTreatment horizon of chronic metabolic disease

Dosing burdenA principal driver of discontinuation

No regenerative optionLoss of β-cell function remains unaddressed

Type 2 diabetes, obesity and NASH affect a very large and growing patient population in China and worldwide, with substantial unmet need for durable, well-tolerated control.
Dosing burden remains a principal driver of discontinuation — the rationale for the weekly and monthly formats across the pipeline.
Single-mechanism agents plateau: weight regain, muscle loss and residual glycaemic drift leave room for multi-target and dual-mechanism approaches.
For early-onset and paediatric diabetes, chronic substitution is an inadequate lifetime proposition — the reason behind the regeneration-oriented programme.

A note on scope

This page describes the clinical problem we are addressing. It is not a market forecast, and no commercial projection is made here.